The benefits of Alzheimer’s treatments donanemab and lecanemab remain too small to justify the additional costs ...

Around 20,000 children and young people with type 1 diabetes in England now benefit from life-changing 'artificial pancreas' technology, recommended by NICE.

Around 3,000 deaths and 5,500 hospital admissions in England caused by chronic heart failure could be prevented each year following our updated draft guideline on medical treatment of the disease.

Around 1,500 people with multiple myeloma are set to benefit from the treatment, which combines belantamab mafodotin (brand name Blenrep) with bortezomib and dexamethasone. These cookies remember ...

Date Update 09 June 2025 The resolution start date for this topic has been delayed. The revised timeline for the evaluation will be available on the topic webpage in due course.

Venetoclax with azacitidine for treating acute myeloid leukaemia before and after an allogeneic stem cell transplant [ID6468] Technology appraisal guidance Venetoclax with ibrutinib for treating ...

There is a simple discount patient access scheme for dostarlimab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact [email protected] ...

There is a simple discount patient access scheme for nivolumab, and a patient access scheme plus commercial access agreement for ipilimumab. NHS organisations can get details on the Commercial Access ...

The lives of thousands of people with chronic kidney disease could be changed for the better after NICE today (Friday, 23 May) recommended a new treatment option for use in the NHS. Just over 4,200 ...

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...

Programme director for Healthtech strategy and development. Imagine a future where groundbreaking health technologies reach NHS patients in a matter of months rather than years. Where innovative ...

Marstacimab is the first under the skin (subcutaneous) injection for severe haemophilia B and today’s decision comes just weeks after the treatment received its UK licence. Given as a once-weekly ...